The Patent Finder

Vasgene Therapeutics, Inc.

Also on record
Records under this name other than the patents Vasgene Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.

Showing 1 to 10 of 10 · Back to Vasgene Therapeutics, Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,533,026Polypeptide compounds for inhibiting angiogenesis and tumor growth
Term ended
Ended no later than Sep 23, 2025 · USPTO record
Term endedEnded no later than Sep 23, 2025USPTO record
US 7,862,816Polypeptide compounds for inhibiting angiogenesis and tumor growth
Lapsed on the fee record
Ended Jan 4, 2023 · USPTO record
Lapsed on the fee recordEnded Jan 4, 2023USPTO record
US 8,273,858Polypeptide compounds for inhibiting angiogenesis and tumor growth
Lapsed on the fee record
Ended Sep 25, 2020 · USPTO record
Lapsed on the fee recordEnded Sep 25, 2020USPTO record
US 7,381,410Polypeptide compounds for inhibiting angiogenesis and tumor growth
Lapsed on the fee record
Ended Jun 3, 2020 · USPTO record
Lapsed on the fee recordEnded Jun 3, 2020USPTO record
US 8,063,183Polypeptide compounds for inhibiting angiogenesis and tumor growth
Lapsed on the fee record
Ended Nov 22, 2019 · USPTO record
Lapsed on the fee recordEnded Nov 22, 2019USPTO record
US 7,977,463Polypeptide compounds for inhibiting angiogenesis and tumor growth
Lapsed on the fee record
Ended Jul 12, 2019 · USPTO record
Lapsed on the fee recordEnded Jul 12, 2019USPTO record
US 8,981,062Polypeptide compounds for inhibiting angiogenesis and tumor growth
Lapsed on the fee record
Ended Mar 17, 2019 · USPTO record
Lapsed on the fee recordEnded Mar 17, 2019USPTO record
US 7,906,116Methods for using and identifying modulators of Delta-like 4
Formerly held
Lapsed on the fee record
Ended Mar 15, 2019 · USPTO record
Lapsed on the fee recordEnded Mar 15, 2019USPTO record
US 8,975,377Cancer treatment using humanized antibodies that bind to EphB4
Lapsed on the fee record
Ended Mar 10, 2019 · USPTO record
Lapsed on the fee recordEnded Mar 10, 2019USPTO record
US 7,585,967Nucleic acid compounds for inhibiting angiogenesis and tumor growth
Lapsed on the fee record
Ended Sep 8, 2013 · USPTO record
Lapsed on the fee recordEnded Sep 8, 2013USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited